In 2016, the difference between the amount that the Medicare drug benefit program reported spending on 29 brand-name combination medications and the estimated spending for generic constituents for the same number of doses was $925 million, according to a study released today by JAMA. This includes $235 million if generic products had been prescribed at the same doses, $219 million using generic substitution at different doses, and $471 million from substitution of similar generic medications in the same therapeutic class. “Promoting generic substitution and therapeutic interchange through prescriber education and more rational substitution policies may offer important opportunities to achieve substantial savings in the Medicare drug benefit program,” the authors wrote.
 

Related News Articles

Headline
The House Ways and Means Committee today held a hearing on “Pathways to Universal Health Coverage,” which debated various options to expand access to health…
Headline
The Centers for Medicare…
Headline
The U.S. Supreme Court today affirmed a D.C. Circuit Court decision that the Department of Health and Human Services violated the Medicare Act when it changed…
Headline
In an evaluation of 49 top-selling brand-name drugs, 28 of the drugs available since 2012 saw an increase in insurer and out-of-pocket costs of more than 50…
Headline
The Centers for Medicare…
Headline
Ways and Means Committee Chairman Richard Neal, D-Mass., and Energy and Commerce Committee Chairman Frank Pallone Jr., D-N.J., along with Ranking Members Kevin…